BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 9816263)

  • 1. Inhibition of the growth of glioblastomas by CGP 41251, an inhibitor of protein kinase C, and by a phorbol ester tumor promoter.
    Begemann M; Kashimawo SA; Choi YA; Kim S; Christiansen KM; Duigou G; Mueller M; Schieren I; Ghosh S; Fabbro D; Lampen NM; Heitjan DF; Schiff PB; Bruce JN; Weinstein IB
    Clin Cancer Res; 1996 Jun; 2(6):1017-30. PubMed ID: 9816263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of human glioblastoma cells with the staurosporine derivative CGP 41251 inhibits CDC2 and CDK2 kinase activity and increases radiation sensitivity.
    Begemann M; Kashimawo SA; Heitjan DF; Schiff PB; Bruce JN; Weinstein IB
    Anticancer Res; 1998; 18(4A):2275-82. PubMed ID: 9703866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CGP 41251 and tamoxifen selectively inhibit mitogen-activated protein kinase activation and c-Fos phosphoprotein induction by substance P in human astrocytoma cells.
    Luo W; Sharif TR; Houghton PJ; Sharif M
    Cell Growth Differ; 1997 Nov; 8(11):1225-40. PubMed ID: 9372245
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential inhibition of the epidermal growth factor-, platelet-derived growth factor-, and protein kinase C-mediated signal transduction pathways by the staurosporine derivative CGP 41251.
    Andrejauskas-Buchdunger E; Regenass U
    Cancer Res; 1992 Oct; 52(19):5353-8. PubMed ID: 1394140
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Growth inhibition induced by Ro 31-8220 and calphostin C in human glioblastoma cell lines is associated with apoptosis and inhibition of CDC2 kinase.
    Begemann M; Kashimawo SA; Lunn RM; Delohery T; Choi YJ; Kim S; Heitjan DF; Santella RM; Schiff PB; Bruce JN; Weinstein IB
    Anticancer Res; 1998; 18(5A):3139-52. PubMed ID: 9858877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of the new selective protein kinase C inhibitor 4'-N-benzoyl staurosporine on cell cycle distribution and growth inhibition in human small cell lung cancer cells.
    Ikegami Y; Yano S; Nakao K
    Arzneimittelforschung; 1996 Feb; 46(2):201-4. PubMed ID: 8720314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor activity of the new selective protein kinase C inhibitor 4'-N-benzoyl staurosporine on murine and human tumor models.
    Ikegami Y; Yano S; Nakao K; Fujita F; Fujita M; Sakamoto Y; Murata N; Isowa K
    Arzneimittelforschung; 1995 Nov; 45(11):1225-30. PubMed ID: 8929245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of ability of protein kinase C inhibitors to arrest cell growth and to alter cellular protein kinase C localisation.
    Courage C; Budworth J; Gescher A
    Br J Cancer; 1995 Apr; 71(4):697-704. PubMed ID: 7710931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protein kinase C and mammary cell differentiation: involvement of protein kinase C alpha in the induction of beta-casein expression.
    Marte BM; Meyer T; Stabel S; Standke GJ; Jaken S; Fabbro D; Hynes NE
    Cell Growth Differ; 1994 Mar; 5(3):239-47. PubMed ID: 8018556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation of the cell cycle at the G2/M boundary in metastatic melanoma cells by 12-O-tetradecanoyl phorbol-13-acetate (TPA) by blocking p34cdc2 kinase activity.
    Arita Y; Buffolino P; Coppock DL
    Exp Cell Res; 1998 Aug; 242(2):381-90. PubMed ID: 9683525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The antitumor activity of doxorubicin against drug-resistant murine carcinoma is enhanced by oral administration of a synthetic staurosporine analogue, CGP 41251.
    Killion JJ; Beltran P; O'Brian CA; Yoon SS; Fan D; Wilson MR; Fidler IJ
    Oncol Res; 1995; 7(9):453-9. PubMed ID: 8835289
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterisation of novel human lung carcinoma cell lines selected for resistance to anti-neoplastic analogues of staurosporine.
    Courage C; Bradder SM; Jones T; Schultze-Mosgau MH; Gescher A
    Int J Cancer; 1997 Nov; 73(5):763-8. PubMed ID: 9398059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cellular relocalisation of protein kinase C-theta caused by staurosporine and some of its analogues.
    Jones T; Courage C; Hubbard A; Gescher A
    Biochem Pharmacol; 1997 May; 53(10):1413-8. PubMed ID: 9260867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor activity of UCN-01, a selective inhibitor of protein kinase C, in murine and human tumor models.
    Akinaga S; Gomi K; Morimoto M; Tamaoki T; Okabe M
    Cancer Res; 1991 Sep; 51(18):4888-92. PubMed ID: 1893379
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A high throughput system for the evaluation of protein kinase C inhibitors based on Elk1 transcriptional activation in human astrocytoma cells.
    Sharif TR; Sharif M
    Int J Oncol; 1999 Feb; 14(2):327-35. PubMed ID: 9917510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A selective protein kinase C inhibitor (CGP 41251) positively and negatively modulates melanoma cell MSH receptors.
    Siegrist W; Sauter P; Eberle AN
    J Recept Signal Transduct Res; 1995; 15(1-4):283-96. PubMed ID: 8903945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A protein kinase C inhibitor induces phenotypic reversion of ras-transformed pancreatic cancer cells and cooperatively blocks tumor cell proliferation with an anti- ras peptide.
    Way D; Smith S; Sivendran S; Chie L; Kanovsky M; Brandt-Rauf PW; Chung DL; Michl J; Pincus MR
    Cancer Chemother Pharmacol; 2002 Jun; 49(6):429-37. PubMed ID: 12107546
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A derivative of staurosporine (CGP 41 251) shows selectivity for protein kinase C inhibition and in vitro anti-proliferative as well as in vivo anti-tumor activity.
    Meyer T; Regenass U; Fabbro D; Alteri E; Rösel J; Müller M; Caravatti G; Matter A
    Int J Cancer; 1989 May; 43(5):851-6. PubMed ID: 2714889
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of a new protein kinase C inhibitor CGP 41251 on T cell functions: inhibition of activation, growth, and target cell killing.
    Alkan SS; Rutschmann S; Grogg D; Erb P
    Cell Immunol; 1993 Aug; 150(1):137-48. PubMed ID: 8102085
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor effect of CGP41251, a new selective protein kinase C inhibitor, on human non-small cell lung cancer cells.
    Ikegami Y; Yano S; Nakao K
    Jpn J Pharmacol; 1996 Jan; 70(1):65-72. PubMed ID: 8822090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.